Business Standard

Serum Institute seeks Rs 100 cr in damages from trial subject

Experts feel trust is broken as trial was not halted; Chennai resident had sought Rs 5 cr in compensation

Photo: Abhishek Waghmare
Premium

A 40-year old man (name witheld) fell sick ten days after he was given a shot in the clinical trial of Covishield - it can be either the vaccine or the placebo

Sohini DasTE Narasimhan Mumbai/Chennai
As questions mount on Oxford-AstraZeneca vaccine trials in India after a 40-year-old participant fell sick and sought damages of Rs 5 crore, Serum Institute of India (SII) has said the allegations in his legal notice are “malicious and misconceived”, and the firm will ask for damages in excess of Rs 100 crore for them.

The SII Chief Executive on Saturday indicated the company would apply to the regulator in two weeks for an emergency use authorisation (EUA) of the vaccine.

The volunteer fell sick 10 days after he was given a shot on October 1 in the clinical trial of

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 29 2020 | 7:40 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com